Hereditary Pancreatic Cancer Panel, Varies
Use
This test is useful for evaluating patients with a personal or family history suggestive of a hereditary pancreatic cancer syndrome. It assists in establishing a diagnosis of a hereditary pancreatic cancer syndrome, which enables targeted cancer surveillance based on the associated risks. By identifying genetic variants associated with an increased risk for pancreatic cancer, the test allows for predictive testing and appropriate screening of at-risk family members. It also informs therapeutic eligibility with poly adenosine diphosphate-ribose polymerase (PARP) inhibitors based on certain gene alterations such as BRCA1 and BRCA2.
Special Instructions
For skin biopsy or cultured fibroblast specimens, a fibroblast culture will be performed at an additional charge. If viable cells are not obtained, the client will be notified. For cord blood specimens that have an accompanying maternal blood specimen, maternal cell contamination studies will be performed at an additional charge.
Limitations
The test identifies single nucleotide and copy number variants in a limited set of 12 genes associated with pancreatic cancer. It does not cover all potential genetic causes of pancreatic cancer and may not detect all types of genetic changes. Additionally, the detection of variants is contingent upon the coverage and quality of the next-generation sequencing process. Reflex testing, such as amniotic fluid culture or maternal cell contamination studies, is performed at an additional charge and may be necessary for complete analysis.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
0-21 days
Related Documents
For more information, please review the documents below
Specimen
Tumor Tissue (FFPE)
Volume
Not provided
Minimum Volume
Not provided